株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

1型糖尿病 (若年性糖尿病) :パイプライン製品の分析

Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 232787
出版日 ページ情報 英文 574 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.37円で換算しております。
Back to Top
1型糖尿病 (若年性糖尿病) :パイプライン製品の分析 Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2017
出版日: 2017年05月30日 ページ情報: 英文 574 Pages
概要

1型糖尿病 (若年性糖尿病) とは、膵臓がインスリンの生産を中断するという自己免疫疾患です。人体の免疫系が膵臓内部のインスリン生産細胞 (β細胞) を攻撃・破壊することで発症します。主な疾病素質として、先天性疾患や家族歴、膵臓疾患、感染症などが挙げられています。主な徴候・症状には、深刻な渇きや頻繁な尿意、極度の空腹感、体重減少、倦怠感、いらつき、非日常的行動などが挙げられます。治療に際しては、生活習慣の改善や提起的な薬物療法が必要となります。

当レポートでは、世界における1型糖尿病 (若年性糖尿病) 治療薬のパイプライン製品の開発状況について分析しており、製品開発・上市の最新動向や治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

型糖尿病 (若年性糖尿病) の概要

治療薬の開発

型糖尿病 (若年性糖尿病):企業で開発中の治療薬

型糖尿病 (若年性糖尿病):大学/機関で研究中の治療薬

型糖尿病 (若年性糖尿病):パイプライン製品の概況

型糖尿病 (若年性糖尿病):企業で開発中の製品

型糖尿病 (若年性糖尿病):大学/機関で研究中の製品

型糖尿病 (若年性糖尿病)の治療薬開発に従事している企業

型糖尿病 (若年性糖尿病):治療薬の評価

薬剤プロファイル

型糖尿病 (若年性糖尿病):最近のパイプライン動向

型糖尿病 (若年性糖尿病):休止中のプロジェクト

型糖尿病 (若年性糖尿病):開発が中止された製品

型糖尿病 (若年性糖尿病):製品開発のマイルストーン

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9357IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2017, provides an overview of the Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline landscape.

Type 1 diabetes (T1D) is an autoimmune disease in which a pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the body's immune system attacks and destroys the insulin-producing cells in the pancreas, called beta cells. Risk factors of type 1 diabetes include genetics and family history, diseases of the pancreas and infection or illness. The signs and symptoms of type 1 diabetes include increased thirst and frequent urination, extreme hunger, weight loss, fatigue, irritability or unusual behavior.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 9, 32, 26, 2, 113, 34 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 2, 32 and 5 molecules, respectively.

Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Type 1 Diabetes (Juvenile Diabetes) - Overview
  • Type 1 Diabetes (Juvenile Diabetes) - Therapeutics Development
  • Type 1 Diabetes (Juvenile Diabetes) - Therapeutics Assessment
  • Type 1 Diabetes (Juvenile Diabetes) - Companies Involved in Therapeutics Development
  • Type 1 Diabetes (Juvenile Diabetes) - Drug Profiles
  • Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects
  • Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products
  • Type 1 Diabetes (Juvenile Diabetes) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..8), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..9), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..10), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..11), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Adocia, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by AiCuris GmbH & Co KG, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Alteogen Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Amarantus Bioscience Holdings Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Amarna Therapeutics BV, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by AntriaBio Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by apceth Biopharma GmbH, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Aphios Corp, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Araim Pharmaceuticals Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Argos Therapeutics Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Astellas Pharma Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by AstraZeneca Plc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Athersys Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Atlantic Bio Sci LLC, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Axxam SpA, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Beta-Cell NV, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Biocon Ltd, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by BioLineRx Ltd, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by BioLingus AG, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Biozeus, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by BirchBioMed Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Caladrius Biosciences Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Cancer Prevention Pharmaceuticals Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Compugen Ltd, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by ConjuChem LLC, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Dance Biopharm Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Denceptor Therapeutics Ltd, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Diabetology (Products) Ltd, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by DiaMedica Therapeutics Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Diamyd Medical AB, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Diasome Pharmaceuticals Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by DiaVacs Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Dompe Farmaceutici SpA, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Eli Lilly and Company, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Ensol Biosciences Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by EpiVax Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Escape Therapeutics Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Evotec AG, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Fate Therapeutics Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Generex Biotechnology Corp, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by GeNeuro SA, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Geropharm LLC, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Gilead Sciences Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Grifols SA, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Heptares Therapeutics Ltd, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by ImmusanT Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Innopharmax Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Intrexon Corp, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Ixchel Pharma LLC, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Johnson & Johnson, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Kadimastem Ltd, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Kamada Ltd, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Kasiak Research Pvt Ltd, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by KPI Therapeutics Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Lexicon Pharmaceuticals Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Ligand Pharmaceuticals Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Lonestar Heart Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by MacroGenics Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Medestea Research & Production SpA, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by MedImmune LLC, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Medtronic Plc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Medy-Tox Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Melior Discovery Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Merck & Co Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Meridigen Biotech Co Ltd, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Neovacs SA, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Novo Nordisk A/S, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Noxxon Pharma AG, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Oramed Pharmaceuticals Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Orgenesis Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by OSE Immunotherapeutics, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Parvus Therapeutics Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Pathfinder Cell Therapy Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Pfizer Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by PharmaCyte Biotech Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by PharmaIN Corp, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Prometheon Pharma LLC, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Purzer Pharmaceutical Co Ltd, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by RedHill Biopharma Ltd, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by REGiMMUNE Corp, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Sanofi, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Selecta Biosciences Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Semma Therapeutics Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Sevion Therapeutics Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Sotio AS, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Tetragenetics Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Thermalin Diabetes LLC, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Toleranzia AB, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Transgene Biotek Ltd, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Traverse Biosciences Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by UCB SA, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Unicyte AG, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by United Therapeutics Corp, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by ViaCyte Inc, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by XL-protein GmbH, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by XOMA Corp, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Zealand Pharma AS, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2017 (Contd..4), H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2017 (Contd..5), H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2017 (Contd..6), H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2017 (Contd..7), H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products, H1 2017
  • Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products, H1 2017 (Contd..1), H1 2017

List of Figures

  • Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top